EPO R/Erythropoietin R hFc Chimera[Biotin], Avi, Human
EPO R/Erythropoietin R HFc Chimera[Biotin], Avi, Human

Immobilized Human EPO, No Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for EPO R/Erythropoietin R hFc Chimera[Biotin], Avi, Human, hFc Tag with the EC50 of 0.70 μg/ml determined by ELISA.

EPO R/Erythropoietin R HFc Chimera[Biotin], Avi, Human

The purity of EPO R/Erythropoietin R hFc Chimera[Biotin], Avi, Human is greater than 95% as determined by SEC-HPLC.

EPO R/Erythropoietin R HFc Chimera[Biotin], Avi, Human

EPO R/Erythropoietin R hFc Chimera[Biotin], Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

EPO R/Erythropoietin R hFc Chimera[Biotin], Avi, Human

The erythropoietin (epo) receptor is a member of the cytokine receptor family. It is expressed almost exclusively on erythroid precursor cells and controls the development of red blood cells. The epo receptor has no intrinsic kinase activity, but binds intracellular tyrosine kinases to elicit its signals. Alterations in the transmission of the signalling cascade lead to clinically abnormal red blood cell production.
Z04447
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
EPO R/Erythropoietin R (Ala25-Pro250)
Accession # P19235-1		 hFc Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 52.58 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • EPO R/Erythropoietin R HFc Chimera[Biotin], Avi, Human
    • EPO R/Erythropoietin R HFc Chimera[Biotin], Avi, Human

    Immobilized Human EPO, No Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for EPO R/Erythropoietin R hFc Chimera[Biotin], Avi, Human, hFc Tag with the EC50 of 0.70 μg/ml determined by ELISA.

  • EPO R/Erythropoietin R HFc Chimera[Biotin], Avi, Human
    • EPO R/Erythropoietin R HFc Chimera[Biotin], Avi, Human

    The purity of EPO R/Erythropoietin R hFc Chimera[Biotin], Avi, Human is greater than 95% as determined by SEC-HPLC.

  • EPO R/Erythropoietin R HFc Chimera[Biotin], Avi, Human
    • EPO R/Erythropoietin R HFc Chimera[Biotin], Avi, Human

    EPO R/Erythropoietin R hFc Chimera[Biotin], Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The erythropoietin (epo) receptor is a member of the cytokine receptor family. It is expressed almost exclusively on erythroid precursor cells and controls the development of red blood cells. The epo receptor has no intrinsic kinase activity, but binds intracellular tyrosine kinases to elicit its signals. Alterations in the transmission of the signalling cascade lead to clinically abnormal red blood cell production.
Synonyms EPO-R; Erythropoietin R; EPO R; EPOR

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.